Area Under the Curve (AUC) values confirmed that PUMA was a good biomarker (AUC > 0.8) for breast, colon and lung cancer, with sensitivities and specificities >80%, except for breast cancer, whose sensitivity reached 92.9% but the specificity was lower (60%). This evidence concerns the gene BBC3 and breast carcinoma.